Ranibizumab - Biologic Drug Details

✉ Email this page to a colleague

▶ Start for $1
Remove trial restrictions

Summary for ranibizumab

Tradenames:	2
High Confidence Patents:	9
Applicants:	2
BLAs:	3
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for ranibizumab
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ranibizumab

Recent Clinical Trials for ranibizumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Sinocelltech Ltd.	Phase 3
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	Phase 3
Bio-Thera Solutions	Phase 3

See all ranibizumab clinical trials

Recent Litigation for ranibizumab

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
LEAR CAPITAL, INC.	2022-03-01
Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc.	2020-06-19
Cytiva Sweden AB v. Bio-Rad Laboratories, Inc.	2018-11-29

See all ranibizumab litigation

PTAB Litigation

Petitioner	Date
Regeneron Pharmaceuticals, Inc. et al.	2021-04-16
Regeneron Pharmaceuticals, Inc.	2020-07-16

See all ranibizumab litigation

Pharmacology for ranibizumab

Mechanism of Action	Vascular Endothelial Growth Factor Inhibitors
Established Pharmacologic Class	Vascular Endothelial Growth Factor Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ranibizumab Derived from Brand-Side Litigation

These patents were obtained from brand-side disclosures in response to biosimilar applications

Glossary

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Patent Expiration
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016	See Plans and Pricing	2022-07-08
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006	See Plans and Pricing	2021-11-01
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018	See Plans and Pricing	2021-11-01
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012	See Plans and Pricing	2034-03-10
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016	See Plans and Pricing	2028-07-08
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012	See Plans and Pricing	2033-09-19
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Patent Expiration